Archives of clinical and biomedical research最新文献

{"title":"Dermoscopic Features of Subcorneal Hematoma on the Palms and Soles: Differences from Acral Melanoma","authors":"Sang-Hyeon Won, Jeongwu Seong, Jungsoo Lee, Kihyuk Shin, Hoon-Soo Kim, Hyun- Chang Ko, Byung-Soo Kim, Moon-Bum Kim","doi":"10.26502/acbr.50170369","DOIUrl":"https://doi.org/10.26502/acbr.50170369","url":null,"abstract":"","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134884588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron and glucose-regulated protein 78: fundamental components in the coinfection of Rhizopus oryzae and SARS-CoV-2","authors":"Manoela Mace, Bárbara Souza da Costa, Rubia do Nascimento Fuentefria, Alexandre Meneghello Fuentefria","doi":"10.22491/2357-9730.122904","DOIUrl":"https://doi.org/10.22491/2357-9730.122904","url":null,"abstract":"Along with the growing number of fatalities and lack of specific treatment at the time, the increasing incidence of mucormycosis worried world health agencies, as it ran the risk of more threatening outcomes for COVID-19 patients. In this context, this review aims to assemble case reports of COVID-19 associated mucormycosis and discuss virulence and host factors involved in the progress of these infections – key aspects that might unveil biological targets and pharmacological approaches to treat these infections. Recently, elevated serum iron levels during SARS-CoV-2 infection have been reported in the literature. Besides being a clinical characteristic of diabetic patients, iron overload is described as a risk factor for Rhizopus oryzae infection. Furthermore, the increased expression of human heat-shock protein GRP78 during iron overload and coronavirus infection display a crucial role as a mediator in Mucorales invasion. These remarkable mechanisms might explain the high incidence of mucormycosis in COVID-19 patients with diabetes and, therefore, suggest regulation of GRP78 expression, management of glycemia and glucocorticoid treatment as potential therapeutic targets of this severe coinfection.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135840002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Características clínicas e sociodemográficas dos usuários de um Centro de Atenção Psicossocial Infantojuvenil em Porto Alegre a partir do sistema de Gerenciamento de Consultas (GERCON)","authors":"Antonella Cabrini de Lima, Juliana Unis Castan, Flávia Moreira Lima","doi":"10.22491/2357-9730.126971","DOIUrl":"https://doi.org/10.22491/2357-9730.126971","url":null,"abstract":"Desde maio de 2019, o acesso aos serviços especializados de saúde mental infantojuvenil do município de Porto Alegre ocorre através da regulação assistencial por intermédio do sistema Gerenciamento de Consultas (GERCON). O objetivo deste estudo foi caracterizar o perfil clínico e sociodemográfico dos usuários encaminhados para um Centro de Atenção Psicossocial Infantojuvenil (CAPSi) nos dois primeiros anos do GERCON.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135843614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Varenicline Efficacy on Tobacco Dependence in Black/African Americans in the United States: A Systematic Review","authors":"Charlene Mansour, V. DeJaco, C. Ahlberg, R. Schreiber","doi":"10.26502/acbr.50170348","DOIUrl":"https://doi.org/10.26502/acbr.50170348","url":null,"abstract":"","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69341392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do IGF1 Polymorphisms Really Matter for Fertility?","authors":"R. N. Veiga, J. S. da Silva, G. F. Gelmini, A. Schuffner, Maria da Graça Bicalho","doi":"10.26502/acbr.50170329","DOIUrl":"https://doi.org/10.26502/acbr.50170329","url":null,"abstract":"","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69341706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCE","authors":"B. Tanriover, Abdulmecit Gungor, M. Al‐Obaidi, B. Thajudeen, R. Wong, I. Mansour, T. Zangeneh, K. Johnson, N. Low, Roshan Alam, Erik Alonso González, B. Sandikçi, S. Muruganpandian, G. Gupta, E. Bedrick, T. Saridogan, K. Mendoza","doi":"10.1101/2022.12.23.22283921","DOIUrl":"https://doi.org/10.1101/2022.12.23.22283921","url":null,"abstract":"BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade neutralizing antibodies, raising concerns about the effectiveness of anti-spike monoclonal antibodies (mAb). METHODS: This study reports a retrospective data analysis in Banner Health Care System. Out of 109,788 adult patients who tested positive for COVID-19, the study cohort was split into patients who received Casirivimab-Imdevimab (Cas-Imd) (N=10,836; Delta-predominant period 6/2021-11/2021) and Sotrovimab (N=998; Omicron-predominant period 12/2021-1/2022) mAb compared to propensity-matched control groups (N=10,836 and N=998), respectively. Index date was the date of mAb administration or the date of positive COVID-19 testing. The primary and secondary outcomes were the incidence of composite outcome (all-cause hospitalization and/or mortality) and ICU admission at 30-days following index date, respectively. RESULTS: Compared to the propensity-matched untreated control cohort, the Cas-Imd mAb reduced the composite outcome (from 7.5% to 3.7%; difference: -3.8% [95% CI: (-4.4%, -3.2%)], p <0.01) regardless of their vaccination status, while Sotrovimab mAb did not (5.0% vs. 3.8%; difference: -1.2% [95% CI: (-3.1%, 0.7%)], p =0.22). In terms of the secondary outcome, similarly Cas-Imd mAb decreased ICU admission during the first hospitalization (from 1.5% to 0.5%; difference: -1.0% [95% CI: (-1.3%, -0.7%)], p <0.01) compared to the control group, whereas Sotrovimab mAb did not (0.9% vs. 0.6%; difference: -0.3% [95% CI: (-1.2%, 0.6%)], p =0.61). Comparing the periods, the Omicron-predominant period was associated with lower composite outcome than that during the Delta-predominant period. CONCLUSIONS: Cas-Imd mAb was effective against the SARS-CoV-2 Delta variant, however sotrovimab lacked efficacy in patients with SARS-CoV-2 Omicron-predominant period.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43573733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID Seq as Laboratory Developed Test (LDT) for diagnosis of SARS-CoV-2 Variants of Concern (VOC)","authors":"R. E. Carpenter, V. Tamrakar, E. Brown, S. Almas, R. Sharma","doi":"10.1101/2022.11.11.22282032","DOIUrl":"https://doi.org/10.1101/2022.11.11.22282032","url":null,"abstract":"Rapid classification and detection of SARS-CoV-2 variants have been critical in comprehending the virus's transmission dynamics. Clinical manifestation of the infection is influenced by comorbidities such as age, immune status, diabetes, and the infecting variant. Thus, clinical management may differ for new variants. For example, some monoclonal antibody treatments are variant-specific. Yet, an FDA-approved test for detecting the SARS-CoV-2 variant is unavailable. A laboratory-developed test (LDT) remains a viable option for reporting the infecting variant for clinical intervention or epidemiological purposes. Accordingly, we have validated the Illumina COVID-Seq assay as an LDT according to the guidelines prescribed by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA). The limit of detection (LOD) of this test is Ct<30 (~15 viral copies) and >200X genomic coverage, and the test is 100% specific in the detection of existing variants. The test demonstrated 100% precision in inter-day, intra-day, and intra-laboratory reproducibility studies. It is also 100% accurate, defined by reference strain testing and split sample testing with other CLIA laboratories. Advanta Genetics LDT COVID Seq has been reviewed by CAP inspectors and is under review by FDA for Emergency Use Authorization.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"6 6 1","pages":"954-970"},"PeriodicalIF":0.0,"publicationDate":"2022-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44228465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unsupervised co-optimization of a graph neural network and a knowledge graph embedding model to prioritize causal genes for Alzheimers Disease","authors":"Li-Yu Daisy Liu, V. Prabhakar","doi":"10.1101/2022.10.03.22280657","DOIUrl":"https://doi.org/10.1101/2022.10.03.22280657","url":null,"abstract":"Data obtained from clinical trials for a given disease often capture reliable empirical features of the highest quality which are limited to few studies/experiments. In contrast, knowledge data extracted from biomedical literature captures a wide range of clinical information relevant to a given disease that may not be as reliable as the experimental data. Therefore, we propose a novel method of training that co-optimizes two AI algorithms on experimental data and knowledge-based information from literature respectively to supplement the learning of one algorithm with that of the other and apply this method to prioritize/rank causal genes for Alzheimer's Disease (AD). One algorithm generates unsupervised embeddings for gene nodes in a protein-protein interaction network associated with experimental data. The other algorithm generates embeddings for the nodes/entities in a knowledge graph constructed from biomedical literature. Both these algorithms are co-optimized to leverage information from each other's domain. Therefore; a downstream inferencing task to rank causal genes for AD ensures the consideration of experimental and literature data available to implicate any given gene in the geneset. Rank-based evaluation metrics computed to validate the gene rankings prioritized by our algorithm showed that the top ranked positions were highly enriched with genes from a ground truth set that were experimentally verified to be causal for the progression of AD. Keywords : Alzheimer's Disease, Causal gene prioritization, Co-optimization, Protein-Protein interaction network, Knowledge Graph","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44237689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organizational impact of an ID NOW COVID-19 point-of-care testing for SARS-CoV2 detection in a maternity ward","authors":"J. Nguyen Van, Benoit Pilmis, Amir Khaterchi, Olivier Billuart, Gauthier Péan De Ponfill, Alban Le Monnier, Elie Azria, A. Mizrahi","doi":"10.1101/2022.08.29.22279161","DOIUrl":"https://doi.org/10.1101/2022.08.29.22279161","url":null,"abstract":"Background SARS-CoV-2 has been responsible for more than 550 million cases of COVID-19 worldwide. RT-PCR is considered the gold standard for the diagnosis of patients suspected of having COVID-19. During the heightened waves of the pandemic, more rapid tests have been required. Point-of-care tests (POCT) for COVID-19 include antigen tests, serological tests, and other molecular-based platforms. The ID NOW COVID-19 assay (Abbott) performs an isothermal gene amplification of a target encoding the RNA-dependent RNA polymerase of SARSCoV-2. The main objective of this study was to evaluate the organizational impact following the implementation of a POC testing platform ID NOW in a maternity ward. Materials and Methods This retrospective study included pregnant women admitted for Groupe Hospitalier Paris Saint- Joseph Paris. The study was conducted over 2 periods lasting 6 months each. The first period (P1) corresponded to the 2nd wave in France (July to December 2020) whereas the second (P2) period focused on the 3rd wave (February to July 2021). During P1, viral detection was performed by RT-PCR at the laboratory. During P2, it was performed with the ID NOW COVID-19 test directly in the delivery room by nursing staff after training and certification. Our primary endpoint was the length of time in the birth room from admission to discharge in the postpartum period. Results 2447 pregnant women were included, 1053 during P1 and 1394 during P2. The median age, percentage of singleton pregnancies, mean gestational age, percentage of nulliparous individuals, percentage of vaginal deliveries, and COVID19 positivity rate were comparable between the two periods. During P2, the length of stay in the delivery room was significantly shorter than during P1 (17.9 vs 14.7 hours, p<0.001). Conclusion Analysis of the data from this study following the implementation of the ID NOW POCT in the maternity ward indicates a significant decrease in the length of stay in the birth room. This outcome needs to be confirmed in a multicenter cohort, in particular to precise the specific impact of COVID-19 care on delays.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43775745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an Accurate and Rapid Antigen Assay for COVID-19 Diagnostics Using Saliva","authors":"C. Troup, D. Mukhopadhyay, T. Chakrabarty, A. Madan, S. Satyanarayana, S. Mehta, S. Dwarakanath","doi":"10.1101/2022.07.10.22277467","DOIUrl":"https://doi.org/10.1101/2022.07.10.22277467","url":null,"abstract":"The global outbreak of COVID-19 highlighted the need for rapid and accurate diagnostic testing to control the spread of this highly contagious disease (1-5). Here, we describe the nCoVega COVID-19 antigen rapid test (~ 15min) that can detect the presence of the SARS-COV-2 virus particles from saliva sample on a portable device. The portable reader instrument, the Vega-200, has a small footprint and is designed for use at point of care settings. The test detects the fluorescence signal using wide-field illumination from antigen-antibody complexes captured on a special filter matrix (6). Results of this clinical evaluation of 183 subjects demonstrates that the nCoVega COVID-19 test performs at par with qRT-PCR tests (7) (gold standard) for both symptomatic and asymptomatic patients with a strong inverse correlation between RFU (relative fluorescence units) and Ct counts (from RT-PCR). Based on a recently-filed EUA application with the FDA, the test has an analytical performance of 15.3 TCID50/mL, and 100% specificity for COVID-19 as compared to other human respiratory viruses, including other human coronaviruses. The test has recently been CE-approved. The working principle of this assay and test system can be used for developing other rapid, inexpensive antigen assays and it can offer an end-to-end, point-of-care solution to meet the continuous demand in tackling existing and emerging infectious diseases across the globe.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48599196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}